Good morning. I'm James Holman from the Washington Post and this is the Daily

2002 for Monday, May 4th. In today's news, the housing market faces its next crisis as may rent and mortgage payments

come due. A city in Oklahoma rescinds its order that people wear masks, and Italy's eight-week lockdown, the world's

longest, is coming to an end. But first, the big idea. Ian Hayden, a healthy 29-year-old reported to a medical clinic in

Seattle last week for a momentous blood draw.

The nurse taking his blood told him it was liquid gold.

Ian is an obscure but important participant

in the most consequential race of a vaccine in medical history.

In early April, he was among the first people in the United States to receive an

experimental vaccine that could help end this coronavirus crisis.

He volunteered to be a test subject, knowing about the risks and the unknowns,

but eager to do his part to help end the worst pandemic in a century.

Scientists at the NIH willemic in a century.

Scientists at the NIH will study blood from Ian and others

for signs that the vaccine triggered an immune response

to a pathogen they have never encountered.

It would be the first preliminary signal that the vaccine

could provide immunity to COVID-19, which has claimed more than 200,000 lives worldwide,

including at least 67,222 of our fellow Americans.

A coronavirus vaccine has become the light at the end of a very long tunnel,

the tool that will bring the virus to heal, allowing us to attend sports events,

hug our friends, celebrate weddings, and grieve at funerals. The goal to deliver a vaccine in 12 to 18 months

...